Prevention and Potential Treatment Strategies for Respiratory Syncytial Virus

被引：9
|
作者：
Sun, Bo-Wen [1 ,2 ]
Zhang, Peng-Peng [1 ,2 ]
Wang, Zong-Hao [1 ,2 ]
Yao, Xia [1 ,2 ]
He, Meng-Lan [1 ,2 ]
Bai, Rui-Ting [1 ,2 ]
Che, Hao [1 ,2 ]
Lin, Jing [3 ]
Xie, Tian [1 ,2 ]
Hui, Zi [1 ,2 ]
Ye, Xiang-Yang [1 ,2 ]
Wang, Li-Wei [1 ,2 ]
机构：
[1] Hangzhou Normal Univ, Sch Pharm, Hangzhou 311121, Peoples R China
[2] Hangzhou Normal Univ, Collaborat Innovat Ctr Tradit Chinese Med Zhejian, Engn Lab Dev & Applicat Tradit Chinese Med, Key Lab Elemene Class Anticanc Chinese Med, Hangzhou 311121, Peoples R China
[3] Hangzhou Haolu Pharma Co, Drug Discovery, Hangzhou 311121, Peoples R China
来源：
MOLECULES | 2024年 / 29卷 / 03期
关键词：
respiratory syncytial virus (RSV); monoclonal antibodies; vaccine; molecule inhibitor; HISTONE DEACETYLASE INHIBITORS; MATRIX PROTEIN; NONSTRUCTURAL PROTEINS; NLRP3; INFLAMMASOME; FUSION INHIBITOR; NUCLEAR EXPORT; YOUNG-CHILDREN; MESSENGER-RNA; N-TERMINUS; P-PROTEIN;
D O I：
10.3390/molecules29030598
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Respiratory syncytial virus (RSV) is a significant viral pathogen that causes respiratory infections in infants, the elderly, and immunocompromised individuals. RSV-related illnesses impose a substantial economic burden worldwide annually. The molecular structure, function, and in vivo interaction mechanisms of RSV have received more comprehensive attention in recent times, and significant progress has been made in developing inhibitors targeting various stages of the RSV replication cycle. These include fusion inhibitors, RSV polymerase inhibitors, and nucleoprotein inhibitors, as well as FDA-approved RSV prophylactic drugs palivizumab and nirsevimab. The research community is hopeful that these developments might provide easier access to knowledge and might spark new ideas for research programs.
引用
收藏
页数：18
相关论文
共 50 条
12345